Open AccessOtsenka riska padeniy zhenshchin s postmenopauzal'nymosteoporozom, poluchayushchikh al'fakal'tsidol
Author(s) -
M. V. Strunina,
M. V. Telyushchenko,
А. А. Попов,
Н. В. Изможерова
Publication year - 2010
Publication title -
osteoporoz i osteopatii
Language(s) - English
Resource type - Journals
eISSN - 2311-0716
pISSN - 2072-2680
DOI - 10.14341/osteo2010215-17
Subject(s) - alfacalcidol , medicine , osteoporosis , prospective cohort study , falling (accident) , bone mineral , physical therapy , vitamin d and neurology , cohort study , environmental health
The study objective: to assess the influence of alfacalcidol treatmenton risk of falling in real clinical practice.Methods. Prospective cohort study included 46 postmenopausalwomen aged from 52 to 78, who had high risk of falling, low bonemineral density, glomerular filtration rate from 65 to 30 ml/min,signed informed consent and were naïve to calcium, vitamin D andantiresorptive agents. All patients have participated in OsteoporosisPatients School Classes, received prescriptions for daily 1 mcg alfacalcidoland approved recommendations on lifestyle modificationsincluding diet, exercises and movement patterns. Individual risk offalling was assessed with the help of Guralnik Short Physical PerformanceBattery Score.Results. There were no new cases of falling and fractures in thecohort during 12 months. During the study period 28 women showedcompliance to alfacalcidol 80% or more (group 1), in 15 patientscompliance was less than 80% (group 2) and 3 women decided toquit the study. Only group 1 demonstrated significant physical functionchanges for the better while there were no significant changesin group 2.Conclusion. In a group of postmenopausal women with high riskof falling and fractures, significant positive changes in lower extremityperformance and balance tests were registered only in womenwith 80% or higher compliance to alfacalcidol consumption.